Cancer treatments are shifting from heavy adjuvant therapies to immunological approaches, such as carT cell therapy. By simultaneously administering two known successful treatments for ALL, Blinatumomab and Kymriah, a high rate of remission can be accomplished in pediatric patients with relapsed ALL. Higher rates of remission, prolonged immunity, and less side effects are the projected results based on previously published studies. Combining these two therapies will likely produce more successful results compared to if the drugs were administered independently. This will hopefully translate into a faster return to daily living activities and less chronic effects during such an important developmental period of a child's life.
Wood, Arleigh, "Adios Adjuvant: Combination Immunotherapy for Pediatric Acute Lymphoblastic Leukemia (ALL) Patients" (2020). Fall Showcase for Research and Creative Inquiry. 80.